Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2018 00:45 ET | Source: Novartis Pharma AG

Novartis schliesst Vereinbarung zum Erwerb von AveXis Inc. für USD 8,7 Mrd ab, um Therapie der SMA zu transformieren und Position als führendes Gentherapie-und Neuroscience-Unternehmen auszubauen

Führender Produktkandidat von AveXis, AVXS-101, hat das Potenzial, erste Genersatztherapie zur einmaligen Anwendung zur Behandlung der spinalen Muskelatrophie (SMA) zu werden eine Krankheit,...
April 09, 2018 00:45 ET | Source: Novartis Pharma AG

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader

AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong...
April 07, 2018 01:15 ET | Source: Novartis Pharma AG

Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation

Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World...
April 04, 2018 11:00 ET | Source: Novartis Pharma AG

Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril

Post-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to...
March 28, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO

Basel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,...
March 27, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren

Preis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf...
March 27, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities

Price reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term...
March 23, 2018 08:51 ET | Source: Novartis Pharma AG

Sandoz receives positive CHMP opinion for proposed biosimilar infliximab

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a...
March 22, 2018 19:30 ET | Source: Novartis Pharma AG

Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate...
March 22, 2018 12:30 ET | Source: Novartis Pharma AG

Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA...